keyword
https://read.qxmd.com/read/38220493/national-diagnostic-and-care-protocols-ndcp-for-hematopoietic-stem-cell-transplantation-in-autoimmune-diseases
#21
JOURNAL ARTICLE
D Farge, G Pugnet, M Allez, C Castilla-Llorente, E Chatelus, P Cintas, C Faucher-Barbey, P Labauge, C Labeyrie, B Lioure, A Maria, D Michonneau, M Puyade, M Talouarn, L Terriou, X Treton, G Wojtasik, H Zephir, Z Marjanovic
Hematopoietic stem cell transplantation (HSCT) for severe ADs was developed over the past 25years and is now validated by national and international medical societies for severe early systemic sclerosis (SSc) and relapsing-remitting multiple sclerosis (MS) and available as part of routine care in accredited center. HSCT is also recommended, with varying levels of evidence, as an alternative treatment for several ADs, when refractory to conventional therapy, including specific cases of connective tissue diseases or vasculitis, inflammatory neurological diseases, and more rarely severe refractory Crohn's disease...
January 13, 2024: La Revue de Médecine Interne
https://read.qxmd.com/read/38202158/myocarditis-and-chronic-inflammatory-cardiomyopathy-from-acute-inflammation-to-chronic-inflammatory-damage-an-update-on-pathophysiology-and-diagnosis
#22
REVIEW
Giuseppe Uccello, Giacomo Bonacchi, Valentina Alice Rossi, Giulia Montrasio, Matteo Beltrami
Acute myocarditis covers a wide spectrum of clinical presentations, from uncomplicated myocarditis to severe forms complicated by hemodynamic instability and ventricular arrhythmias; however, all these forms are characterized by acute myocardial inflammation. The term "chronic inflammatory cardiomyopathy" describes a persistent/chronic inflammatory condition with a clinical phenotype of dilated and/or hypokinetic cardiomyopathy associated with symptoms of heart failure and increased risk for arrhythmias. A continuum can be identified between these two conditions...
December 27, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/38149621/best-clinical-practice-in-the-treatment-of-juvenile-systemic-sclerosis-expert-panel-guidance-the-result-of-the-international-hamburg-consensus-meeting-december-2022
#23
REVIEW
Ivan Foeldvari, Kathryn S Torok, Jordi Antón, Michael Blakley, Tamás Constantin, Maurizio Cutolo, Christopher P Denton, Kim Fligelstone, Bernd Hinrichs, Suzanne C Li, Susan Maillard, Edoardo Marrani, Pia Moinzadeh, Catherine H Orteu, Clare E Pain, John D Pauling, Clarissa Pilkington, Franziska Rosser, Vanessa Smith, Daniel F Furst
INTRODUCTION: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently there is only one consensus treatment guideline concerning skin, pulmonary and vascular involvement for jSSc, the jSSc SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) initiative, which was based on data procured up to 2014. Therefore, an update of these guidelines, with a more recent literature and expert experience, and extension of the guidance to more aspects of the disease is needed...
December 27, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/38146100/performance-of-detect-pulmonary-arterial-hypertension-algorithm-according-to-the-hemodynamic-definition-of-pulmonary-arterial-hypertension-in-the-2022-european-society-of-cardiology-and-the-european-respiratory-society-guidelines
#24
JOURNAL ARTICLE
Oliver Distler, Diana Bonderman, J Gerry Coghlan, Christopher P Denton, Ekkehard Grünig, Dinesh Khanna, Vallerie V McLaughlin, Ulf Müller-Ladner, Janet E Pope, Madelon C Vonk, Lilla Di Scala, Jean-Christophe Lemarie, Loïc Perchenet, Éric Hachulla
OBJECTIVE: The evidence-based DETECT pulmonary arterial hypertension (PAH) algorithm is frequently used in patients with systemic sclerosis (SSc) to help clinicians screen for PAH by using noninvasive data to recommend patient referral to echocardiography and, if applicable, for a diagnostic right-sided heart catheterization. However, the hemodynamic definition of PAH was recently updated in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines. The performance of DETECT PAH in identifying patients with a high risk of PAH according to this new definition was assessed...
December 25, 2023: Arthritis & Rheumatology
https://read.qxmd.com/read/38135175/pulmonary-arterial-hypertension-associated-with-connective-tissue-diseases-ctd-pah-recent-and-advanced-data
#25
REVIEW
Benjamin Thoreau, Luc Mouthon
Pulmonary arterial hypertension (PAH), corresponding to group 1 of pulmonary hypertension classification, is a rare disease with a major prognostic impact on morbidity and mortality. PAH can be either primary in idiopathic and heritable forms or secondary to other conditions including connective tissue diseases (CTD-PAH). Within CTD-PAH, the leading cause of PAH is systemic sclerosis (SSc) in Western countries, whereas systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) are predominantly associated with PAH in Asia...
December 20, 2023: Autoimmunity Reviews
https://read.qxmd.com/read/38123338/unmet-need-in-rheumatology-reports-from-the-advances-in-targeted-therapies-meeting-2023
#26
JOURNAL ARTICLE
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John D Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie Crofford, Ronald F van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Tom Wj Huizinga, Ellen M Gravallese
The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the major unmet scientific needs in rheumatology. The 23rd annual Advances in Targeted Therapies meeting convened with more than 100 international basic scientists and clinical researchers in rheumatology, immunology, infectious diseases, epidemiology, molecular biology and other specialties relating to all aspects of immune-mediated inflammatory diseases...
March 12, 2024: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/38107443/pregnancy-outcomes-in-female-multiple-sclerosis-patients-exposed-to-intramuscular-interferon-beta-1a-or-peginterferon-beta-1a-reported-in-a-german-patient-support-programme-results-from-the-non-interventional-post-authorization-safety-study-prima
#27
JOURNAL ARTICLE
Juliane Klehmet, Yvonne Begus-Nahrmann, Kirsi Taipale, Gabriele Niemczyk, Karin Rehberg-Weber
BACKGROUND: Based on data from two large cohort studies, a label update became applicable for the class of interferon beta therapies in 9/2019, allowing interferons during pregnancy and breastfeeding. OBJECTIVE: To assess pregnancy outcomes of women with multiple sclerosis (MS) exposed to peginterferon beta-1a or intramuscular interferon beta-1a therapy (IFN). DESIGN: Non-interventional post-authorization safety study. METHODS: PRIMA was conducted from April to October 2021 in Germany...
2023: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38061621/risks-and-outcomes-of-pregnancy-in-neuromyelitis-optica-spectrum-disorder-a-comprehensive-review
#28
REVIEW
Pakeeran Siriratnam, Saif Huda, Helmut Butzkueven, Anneke van der Walt, Vilija Jokubaitis, Mastura Monif
Neuromyelitis optica spectrum disorder (NMOSD) is a rare central nervous system autoimmune disease. Aquaporin-4 antibody (AQP4-IgG) is present in over 75% of cases and criteria also exist for the diagnosis of seronegative NMOSD. AQP4-IgG NMOSD has a strong female predominance (9:1 ratio), with a median onset age of 40 years. Pregnancy in those with NMOSD is therefore an important topic. Fecundity in NMOSD is likely impaired, and for females who conceive, obstetric complications including miscarriages and pre-eclampsia are significantly higher in NMOSD compared to the general population and in related conditions such as multiple sclerosis (MS)...
December 5, 2023: Autoimmunity Reviews
https://read.qxmd.com/read/38058171/an-update-on-combination-therapies-for-multiple-sclerosis-where-are-we-now
#29
REVIEW
Per Soelberg Sorensen, Melinda Magyari, Finn Sellebjerg
INTRODUCTION: In theory, combination of two agents, which are suboptimal when given individually, may result in a significant increase in therapeutic effect. Combination therapies have proven particularly effective against infections such as HIV, cancer, and also chronic autoimmune diseases such as rheumatoid arthritis. AREAS COVERED: The authors review the literature, searching for randomized placebo-controlled or comparative, double-blind or investigator-blinded clinical trials, not including open label clinical trials, of treatment of multiple sclerosis (MS) with combination therapy or add-on therapy, including trials of induction therapy, trials for prevention of disease activity or worsening, amelioration of adverse effects, and treatment of relapses, and trials to increase remyelination...
December 6, 2023: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/38043675/examination-of-risk-factors-associated-with-falls-and-injurious-falls-in-people-with-multiple-sclerosis-an-updated-nationwide-study
#30
JOURNAL ARTICLE
Libak Abou, Chloe McCloskey, Cory Wernimont, Nora E Fritz, Anna L Kratz
OBJECTIVE: To provide an update on risk factors associated with falls and injurious falls among people with multiple sclerosis (PwMS) in the United States. DESIGN: Nationwide cross-sectional web-based survey SETTING: Community setting PARTICIPANTS: Adult PwMS (n = 965) INTERVENTIONS: Not applicable MAIN OUTCOME MEASURES: Participants completed self-report surveys of demographics, clinical data, concerns about falling, occurrence of falls, factors associated with falls, and injurious falls in the past 6 months...
December 1, 2023: Archives of Physical Medicine and Rehabilitation
https://read.qxmd.com/read/38008300/current-knowledge-on-multiple-sclerosis-pathophysiology-disability-progression-assessment-and-treatment-options-and-the-role-of-autologous-hematopoietic-stem-cell-transplantation
#31
REVIEW
Georgios Gakis, Ioannis Angelopoulos, Ioannis Panagoulias, Athanasia Mouzaki
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that affects nearly 2.8 million people each year. MS distinguishes three main types: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). RRMS is the most common type, with the majority of patients eventually progressing to SPMS, in which neurological development is constant, whereas PPMS is characterized by a progressive course from disease onset. New or additional insights into the role of effector and regulatory cells of the immune and CNS systems, Epstein-Barr virus (EBV) infection, and the microbiome in the pathophysiology of MS have emerged, which may lead to the development of more targeted therapies that can halt or reverse neurodegeneration...
November 25, 2023: Autoimmunity Reviews
https://read.qxmd.com/read/37986728/plug-and-play-stability-for-intracortical-brain-computer-interfaces-a-one-year-demonstration-of-seamless-brain-to-text-communication
#32
Chaofei Fan, Nick Hahn, Foram Kamdar, Donald Avansino, Guy H Wilson, Leigh Hochberg, Krishna V Shenoy, Jaimie M Henderson, Francis R Willett
Intracortical brain-computer interfaces (iBCIs) have shown promise for restoring rapid communication to people with neurological disorders such as amyotrophic lateral sclerosis (ALS). However, to maintain high performance over time, iBCIs typically need frequent recalibration to combat changes in the neural recordings that accrue over days. This requires iBCI users to stop using the iBCI and engage in supervised data collection, making the iBCI system hard to use. In this paper, we propose a method that enables self-recalibration of communication iBCIs without interrupting the user...
November 6, 2023: ArXiv
https://read.qxmd.com/read/37980267/-update-on-targeted-biopharmaceuticals-in-systemic-sclerosis
#33
JOURNAL ARTICLE
B Chaigne, L Mouthon
Systemic sclerosis (SSc) is a rare connective tissue disease characterized by inflammation, fibrosis, and autoimmunity. Despite few clinical trials when compared to other autoimmune diseases, SSc has benefited from renewed interest over the past ten years and a large number of clinical trials have been performed or are underway. We present here the results of the trials published in the last 5 years in ScS according to the chosen endpoint criteria and describe the trials in progress or expected in the years to come...
November 16, 2023: La Revue de Médecine Interne
https://read.qxmd.com/read/37974959/microtubule-stabilising-peptides-new-paradigm-towards-management-of-neuronal-disorders
#34
REVIEW
Shubhangi Bhargava, Riya Kulkarni, Bhaskar Dewangan, Neeraj Kulkarni, Chirag Jiaswar, Kunal Kumar, Amit Kumar, Praveen Reddy Bodhe, Hemant Kumar, Bichismita Sahu
Neuronal cells made of soma, axon, and dendrites are highly compartmentalized and possess a specialized transport system that can convey long-distance electrical signals for the cross-talk. The transport system is made up of microtubule (MT) polymers and MT-binding proteins. MTs play vital and diverse roles in various cellular processes. Therefore, defects and dysregulation of MTs and their binding proteins lead to many neurological disorders as exemplified by Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and many others...
November 15, 2023: RSC medicinal chemistry
https://read.qxmd.com/read/37930795/executive-functions-in-relapsing-remitting-multiple-sclerosis
#35
JOURNAL ARTICLE
M Rosa Elosúa, Noelia Villadangos
Some studies suggest that patients with relapsing-remitting multiple sclerosis have problems in the functioning of working memory, and more specifically in executive functions, but the available results are still inconsistent. The aim of the present study was to examine executive functioning in multiple sclerosis using classical and representative tasks for divided attention, updating, attentional shifting, and inhibition. The sample was composed of 48 participants aged between 18 and 59 years (24 persons living with multiple sclerosis and 24 healthy participants matched in age and education level)...
November 6, 2023: Applied Neuropsychology. Adult
https://read.qxmd.com/read/37919037/updated-genotype-phenotype-correlations-in-tsc
#36
REVIEW
Paolo Curatolo, Marina Trivisano, Nicola Specchio
Paolo Curatolo MD, Romina Moavero MD, Denis Roberto, Federica Graziola Seminars in Pediatric Neurology Volume 22, Issue 4, December 2015, Pages 259-273 Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the development of widespread hamartomatous lesions in various organs, including brain, skin, kidneys, heart, and eyes. Central nervous system is almost invariably involved, with up to 85% of patients presenting with epilepsy, and at least half of patients having intellectual disability or other neuropsychiatric disorders including autism spectrum disorder...
October 2023: Seminars in Pediatric Neurology
https://read.qxmd.com/read/37906785/-multidisciplinary-care-and-therapeutic-advances-in-amyotrophic-lateral-sclerosis
#37
JOURNAL ARTICLE
José Manuel Matamala, Javier Moreno-Roco, Ignacio Acosta, Ricardo Hughes, Patricia Lillo, Juan Carlos Casar, Nicholas Earle
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that mainly affects the motor system, resulting in progressive weakness and muscle wasting. Despite the tremendous advances in physiopathological and clinical characterization, we do not have a curative treatment yet. The progressive and fatal course of ALS makes its management particularly complex and challenging given the diversity of symptoms presenting during the disease progression. The main goal in the treatment of ALS patients is to minimize morbidity and maximize the quality of life...
December 2022: Revista Médica de Chile
https://read.qxmd.com/read/37906297/an-updated-meta-analysis-of-effectiveness-and-safety-of-mtor-inhibitors-in-the-management-of-tuberous-sclerosis-complex-patients
#38
JOURNAL ARTICLE
Mengling Liu, Jiayou Ye, Xiaoling You
PURPOSE: Tuberculous sclerosis complex (TSC) is an autosomal dominant multi-system disease. In TSC patients, the inhibition of mTOR pathway is weakened, which leads to the uncontrolled proliferation of normal resting cells. Therefore, mTOR inhibitors have many therapeutic potentials in the treatment of TSC. However, there is no consensus on the safety and efficacy of mTOR inhibitors so far. This article aimed to present new evidence for the efficacy and safety of mTOR inhibitors in the treatment of TSC by evaluating published clinical trials...
October 31, 2023: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
https://read.qxmd.com/read/37880997/safety-of-exercise-training-in-multiple-sclerosis-an-updated-systematic-review-and-meta-analysis
#39
JOURNAL ARTICLE
Yvonne C Learmonth, Matthew P Herring, Daniel I Russell, Lara A Pilutti, Sandra Day, Claudia H Marck, Bryan Chan, Alexandra P Metse, Robert W Motl
BACKGROUND: A review of the safety profile of exercise training in multiple sclerosis (MS) has not been conducted since 2013. OBJECTIVE: We undertook a systematic review and meta-analysis of randomised controlled trials (RCTs) of exercise training published since 2013 and quantified estimated population risks of clinical relapse, adverse events (AE) and serious adverse event (SAE). METHODS: Articles reporting safety outcomes from comparisons of exercise training with non-exercise among persons with MS were identified...
November 2023: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/37868834/biomarkers-in-the-pathogenesis-diagnosis-and-treatment-of-systemic-sclerosis
#40
REVIEW
Maheswari Muruganandam, Angie Ariza-Hutchinson, Rosemina A Patel, Wilmer L Sibbitt
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, vasoinstability, and decreased perfusion with ischemia, inflammation, and exuberant fibrosis of the skin and internal organs. Biomarkers are analytic indicators of the biological and disease processes within an individual that can be accurately and reproducibly measured. The field of biomarkers in SSc is complex as recent studies have implicated at least 240 pathways and dysregulated proteins in SSc pathogenesis. Anti-nuclear antibodies (ANA) are classical biomarkers with well-described clinical classifications and are present in more than 90% of SSc patients and include anti-centromere, anti-Th/To, anti-RNA polymerase III, and anti-topoisomerase I antibodies...
2023: Journal of Inflammation Research
keyword
keyword
95025
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.